p53 gene status and modulation of response to cisplatin chemotherapy in non-small cell lung cancer cells

被引：0
|
作者：
Barr, M. P. [1 ,2 ]
Batina, M. B. [1 ,2 ]
Cuffe, S. [1 ,2 ]
Finn, S. [1 ,2 ,3 ]
O'Byrne, K. J. [1 ,2 ,4 ]
机构：
[1] St James Hosp, Thorac Oncol Res Grp, Dublin, Ireland
[2] Univ Dublin Trinity Coll, Dublin 2, Ireland
[3] St James Hosp, Dept Histopathol, Dublin, Ireland
[4] Queensland Univ Technol, Canc & Ageing Res Program, Brisbane, Qld 4001, Australia
来源：
LUNG CANCER | 2014年 / 83卷
关键词：
D O I：
10.1016/S0169-5002(14)70003-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [31] P53 codon 72 polymorphism increases the risk of somatic P53 gene mutations in non-small cell lung cancer (NSCLC)
    Szymanowska, A
    Jassem, E
    Dziadziuszko, R
    Borg, A
    Limon, J
    Kobierska-Gulida, G
    Skokowski, J
    Jassem, J
    LUNG CANCER, 2005, 49 : S75 - S75
  • [32] Relation between P53 codon 72 polymorphism and somatic P53 gene mutation in non-small cell lung cancer (NSCLC)
    Jassem, J.
    Szymanowska, A.
    Jassem, E.
    Dziadziuszko, R.
    Borg, A.
    Limon, J.
    Kobierska-Gulida, G.
    Skokowski, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 336 - 336
  • [33] Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer
    Tanaka, F
    Otake, Y
    Yanagihara, K
    Yamada, T
    Miyahara, R
    Kawano, Y
    Li, M
    Inui, K
    Wada, H
    BRITISH JOURNAL OF CANCER, 2001, 84 (02) : 263 - 269
  • [34] Prognostic significance of p53 status in non-small cell lung cancer in correlation with postoperative adjuvant therapy
    Hanaoka, N
    Tanaka, F
    Wada, H
    THORACIC AND CARDIOVASCULAR SURGEON, 2002, 50 (06): : 355 - 359
  • [35] Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer
    F Tanaka
    Y Otake
    K Yanagihara
    T Yamada
    R Miyahara
    Y Kawano
    M Li
    K Inui
    H Wada
    British Journal of Cancer, 2001, 84 : 263 - 269
  • [36] Correlation of p53 genotype and response to induction chemotherapy in advanced non small cell lung cancer (NSCLC).
    Kandioler, D
    Kappel, S
    Eberhardt, W
    Stamatis, G
    Mittelböck, M
    Bachleitner-Hoffmann, T
    Zöchbauer-Müller, S
    Aigner, C
    Klepetko, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 631S - 631S
  • [37] Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer
    Nakano, J
    Huang, CL
    Liu, DG
    Ueno, M
    Sumitomo, S
    Yokomise, H
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 27 (05) : 1215 - 1221
  • [38] Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells
    Tortelli, Tharcisio Citrangulo, Jr.
    Tamura, Rodrigo Esaki
    Junqueira, Mara de Souza
    Mororo, Janio da Silva
    Bustos, Silvina Odete
    Natalino, Renato Jose Mendonca
    Russell, Shonagh
    Desaubry, Laurent
    Strauss, Bryan Eric
    Chammas, Roger
    AGING-US, 2021, 13 (18): : 21914 - 21940
  • [39] CHEMOTHERAPY OF NON-SMALL CELL LUNG-CANCER WITH CISPLATIN AND VINDESINE
    DRINGS, P
    KLECKOW, M
    MANKE, HG
    STIEFEL, E
    ONKOLOGIE, 1984, 7 (04): : 202 - 204
  • [40] Cisplatin plus vinorelbine chemotherapy for non-small cell lung cancer
    Pereira, JR
    Gampel, O
    Martins, SJ
    Ikari, FK
    Nikaedo, SM
    Paschoalini, M
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 643 - 646
12345